Mitochondrial morphometrics in idiopathic Parkinson‘s disease fibroblasts
Objective: To identify mitochondrial morphometric phenotypes in fibroblasts derived from patients with idiopathic Parkinson’s disease (IPD). Background: Mitochondrial dysfunction (MD) has been proposed as cellular…Final MDS-UPDRS, Part IV Results of the EASE LID 2 Study: Long Term, Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients
Objective: An objective of this study was to evaluate the long-term duration of ADS-5102 effect on dyskinesia as assessed by the Unified Parkinson’s Disease Rating…Effectiveness of a Multi-disciplinary Parkinson’s Disease (PD) Clinic: A 2-year Prospective Observational Study
Objective: To evaluate if a multi-disciplinary PD clinic can result in better outcome in PD patients in 2 years. Background: PD is a neurodegenerative disease…Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson’s Disease – INSIGHTS Study
Objective: To examine levodopa-carbidopa intestinal gel, LCIG (also known as carbidopa-levodopa enteral suspension in the US), on non-motor symptoms (NMS) compared with individually-optimized, conventional PD…Oral treatment with JNX3001 protects dopaminergic function in a non-human primate model of Parkinson’s disease alpha-synucleinopathy
Objective: We evaluated the efficacy of JNX3001 in an aSyn-based macaque model with plasma exposures associated with efficacy in rodents. Background: Alpha-synuclein (aSyn) deposition is…PROtein, LEucine And vitamin D Enhancing Rehabilitation (PRO-LEADER) in patients with Parkinson’s disease or parkinsonism: A RCT
Objective: We evaluated the efficacy of a muscle-targeted nutritional support on the outcomes of a multidisciplinary intensive rehabilitation treatment (MIRT). Background: Physical rehabilitation is an…Dysphagia predicts poor outcome in late-stage Parkinson’s disease
Objective: to evaluate the clinical progression and prognostic factors of a late-stage PD (LSPD) population. Background: Parkinson’s disease (PD) disability milestones emerge in an exponential…A single center retrospective analysis of Opicapone treatment in 90 Parkinson patients
Objective: To evaluate retrospectively the treatment with the novel COMT-inhibitor opicapone (OPC) in a tertiary Parkinson Center the first year after its approval in Germany…Double-blind controlled trial of Spectramax™ light therapy for the treatment of Parkinson’s disease patients on stable dopaminergic therapy
Objective: To evaluate the safety and effectiveness of Spectramax™ specialized bandwidth light therapy (LT) as adjunctive treatment in Parkinson’s disease (PD). Background: Previous studies have…Frequency-dependent effects of subthalamic deep brain stimulation on motor symptoms in Parkinson’s disease
Objective: This study aims to investigate whether low-frequency stimulation (LFS) (100Hz, mostly 130 or 150 Hz) in deep brain stimulation (DBS) targeting subthalamic nucleus (STN).…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.